MB07811: Phase II started

Viking began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 5 and 10 mg oral VK2809 once daily for 12 weeks in about 80 patients with elevated LDL-C and NAFLD. The company has exc...